(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 February 2005 (17.02.2005)

PCT

(10) International Publication Number
WO 2005/013956 A1

(51) International Patent Classification[7]: A61K 31/155, 31/4439, 9/28, A61P 3/10

(21) International Application Number: PCT/EP2004/008970

(22) International Filing Date: 9 August 2004 (09.08.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0318824.0 11 August 2003 (11.08.2003) GB

(71) Applicant *(for all designated States except US)*: **SB PHARMCO PUERTO RICO INC.** [US/US]; The Prentice Hall Corp. System of P.R. Inc., c/o FGR Corporate Services Inc., BBV Tower, 8th Floor, 254 Munoz Rivera Avenue (PR).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **COLES, Peter, John** [CA/CA]; GlaxoSmithKline Inc., 7333 Mississauga Road North, Mississauga, Ontario L5N 6L4 (CA). **MACKENZIE, Donald, Colin** [GB/US]; GlaxoSmithKline (CIDRA), Road 172 Km 9.1, Bo. Certenejas, Cidra, Puerto Rico, 00739-1975 (PR). **MUDD, Paul, Norman, Jnr** [US/US]; GlaxoSmithKline, Five Moore Drive, Research Triangle Park, North Carolina 27709 (US).

(74) Agent: **GIDDINGS, Peter, John**; GlaxoSmithKline, Corporate Intellectual Property (CN925.1), 980 Great West Road, Brentford Middlesex TW8 9GS (GB).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

[Continued on next page]

(54) Title: NOVEL COMPOSITION COMPRISING ROSIGLITAZONE AND ANOTHER ANTIDIABETIC AGENT



(57) Abstract: An oral dosage form comprising an erodable core, which core comprises rosiglitazone or a pharmaceutically acceptable salt or solvate thereof and another antidiabetic agent, the core having a coating with one or more openings, characterised in that the coating is erodable under predetermined pH conditions; a process for preparing such a dosage form and the use of such a dosage form in medicine.

WO 2005/013956 A1

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.